About this trial
The aim of this clinical trial is to compare the efficacy of a 16-week center-based Pivotal Response Treatment (PRT-C) versus home-based Pivotal Response Treatment (PRT-H) in targeting social communication deficits in young children with autism spectrum disorder (ASD) with significant language delay. The two groups will also be compared to a control group that consists of children who are receiving treatment as usual (TAU).
Eligibility criteria
Qualifiers
Diagnosis of Autism Spectrum Disorder (ASD) based on Autism Diagnostic Interview Revised (ADI-R), Autism Diagnostic Observation Schedule, Second Edition (ADOS-2) or Childhood Autism Rating Scale, Second Edition (CARS-2), Diagnostic and Statistical Manual 5th Edition (DSM-5), and expert clinical opinion;
Boys and girls between 2.0 and 5.11 years;
Ability to participate in the testing procedures to the extent that valid standard scores can be obtained;
Language delay as measured by the Preschool Language Scale, 5th Edition (PLS-5): Standard score at least 1 standard deviation below average for expressive language ability for 2 and 3 year olds; 2 standard deviations for 4 year olds, and 3 standard deviations for 5 year olds;
Disqualifiers
Current or lifetime diagnosis of severe psychiatric disorder (e.g., bipolar disorder, etc.);
Receiving ABA of 15 hours or more;
Presence of active medical problem (e.g., unstable seizure disorder or heart disease);
Previous adequate Pivotal Response Treatment (PRT) trial;
Trial design
Treatments tested in this trial
- Center-Based Pivotal Response Treatment (PRT) Intervention (PRT-C)
- Home-Based Pivotal Response Treatment (PRT Intervention (PRT-H)
Treatment groups
Sponsors and collaborators
Stanford University
Lead sponsor
Anonymous Donor
Collaborator